This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gordon, C. R. Articles by Shupak, A. Search for Related Content PubMed PubMed Citation Articles by Gordon, C. R. Articles by Shupak, A. Social Bookmarking                         What's this?

The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance

Motion Sickness and Human Performance Laboratory, Israel Naval Medical Institute, PO Box 8040, 31 080 Haifa, Israel; cgordon{at}post.tau.ac.il

A. Gonen

Z. Nachum

I. Doweck

O. Spitzer

A. Shupak

Department of Neurology, Meir General Hospital, Kfar Saba and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

We assessed the influence of dimenhydrinate, cinnarizine and transdermal scopolamine on the ability to perform simulated naval crew tasks. The effect of single doses of dimenhydrinate, 100 mg, cinnarizine, 50 mg, and one transdermal scopolamine patch on psychomotor performance was evaluated using a double-blind, placebo-controlled, randomized, crossover design in three separate studies. A total of 60 young naval crew (20 for dimenhydrinate, 15 for cinnarizine and 25 for transdermal scopolamine) underwent a battery of computerized and paper and pencil performance tests, and filled out a questionnaire on side-effects and well-being self-assessment. Dimenhydrinate significantly impaired decision reaction time and auditory digit span. Most of the subjects who took dimenhydrinate also reported a subjective decrease in well-being and general performance abilities. Cinnarizine and transdermal scopolamine did not affect performance abilities. Cinnarizine was free of significant side-effects. Dry mouth was the only significant side-effect of transdermal scopolamine. These findings could be explained by the well-known sedative properties of dimenhydrinate and not by a specific effect on any particular cognitive or motor function. Our results suggest that dimenhydrinate, 100 mg, adversely affects psychomotor function, whereas single doses of cinnarizine, 50 mg, and transdermal scopolamine appear to be free of side-effects on performance and seem to be a preferable anti-seasickness drug for use by a naval crew.

Key Words: cinnarizine • dimenhydrinate • drowsiness • performance • scopolamine • seasickness • sedation

Journal of Psychopharmacology, Vol. 15, No. 3, 167-172 (2001)
DOI: 10.1177/026988110101500311


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. E. R. Simons Advances in H1-Antihistamines N. Engl. J. Med., November 18, 2004; 351(21): 2203 - 2217. [Full Text] [PDF]

				C. Scully and J.-V. Bagan ADVERSE DRUG REACTIONS IN THE OROFACIAL REGION Critical Reviews in Oral Biology & Medicine, July 1, 2004; 15(4): 221 - 239. [Abstract] [Full Text] [PDF]